A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

ViiV Healthcare

Status

Conditions: Human Immunodeficiency Virus (HIV)

Treatments: Drug: Open Label Treatment Access: Maraviroc

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT00992654

A4001096

A4001050

Details and patient eligibility

About

The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc.
• Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures.

Exclusion criteria

• Subjects who discontinued in A4001050 study.
• Unable to provide consent.